undamentalytics Newsletter
Sign in

Cumberland Pharmaceuticals Inc balance sheet

At the end of fiscal 2025, Cumberland Pharmaceuticals Inc had total assets of $76.8m, total liabilities of $52.3m and shareholders' equity of $24.9m. It held $11.4m in cash against $5.2m of debt: net cash of $6.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents79667154414038354528282527201818114
Receivables—57656678881271310121713
Inventory—86666457129118105400
Total current assets—8187876971656669595050464636363734
Goodwill————————011111111—
Total assets—929699889592939311310596849382767763
Accounts payable—22323389111013101114141920
Deferred revenue (current)————————————01000—
Total current liabilities—978814121518282426192928323735
Short-term debt—30———————————050—
Total debt05540024102019151516132050
Total liabilities—141313815152029575350425753535246
Shareholders' equity727883867981777364565147433630232517
Net debt (negative = net cash)−79−61−66−50−41−40−37−30−36−8−10−10−12−4−62−6−4
Shares outstanding—20m20m19m18m17m16m16m16m15m15m15m15m14m14m14m15m15m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CPIX vs IMCCBGM vs CPIXCPIX vs SBFMBFRI vs CPIX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Cumberland Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cumberland Pharmaceuticals Inc.